--- title: "Immunovant (IMVT) stock news, pipeline, cash and catalysts" url: "https://aibio.space/companies/immunovant/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Immunovant news for investors: Immunovant is a Roivant-controlled biotech developing IMVT-1402, an injected antibody that lowers IgG by blocking the FcRn…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Immunovant is down to one drug and a long wait for proof Immunovant has cut down to one drug and a clear calendar, with enough cash to reach its 2027 Graves' disease and myasthenia gravis readouts. Two misses in 2026 have weakened the case that deeper IgG lowering always wins. The randomized part of the arthritis trial and the 2027 data will decide whether IMVT-1402 stands apart from approved FcRn drugs. Read the full desk view aibio.space Investor Rank · Opinion **3** /10 Negative view Cash reaches the 2027 readouts, but the company is down to IMVT-1402 after a phase 3 miss and a lupus miss, in markets with approved FcRn drugs. - **Technology**: 1/2 - **Odds**: 0/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 0/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Mechanism validated, drug not yet.** FcRn blockers are approved in myasthenia gravis, but IMVT-1402's only published patient efficacy numbers so far are open-label. - **Odds**: **Mixed track record.** Batoclimab missed in phase 3 and IMVT-1402 missed in cutaneous lupus, while open-label arthritis data looked strong. - **Balance sheet**: **Funded into 2027 readouts.** Cash was $797.8 million at June 30 after a $153.2 million quarterly loss. - **Main risk**: **Single-asset concentration.** All value now sits on IMVT-1402, in markets where argenx and others are already selling FcRn drugs. - **Watch next**: **Arthritis update first.** The difficult-to-treat RA program update is due in the second half of 2026, then Graves' and myasthenia data in 2027. ## Top news on Immunovant ## Dates **Second half of calendar 2026** Further update on the potentially registrational difficult-to-treat rheumatoid arthritis program [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) **Nov. 9, 2026** Fiscal second-quarter results and business update [Source](https://www.immunovant.com/investors/news-events/press-releases) **Calendar 2027** Topline data from potentially registrational trials in Graves' disease and myasthenia gravis [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) **Calendar 2028** Topline data in CIDP and Sjogren's disease [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) ## The money $797.8 million in cash and cash equivalents at June 30, 2026 (fiscal Q1 2027), which Immunovant says provides runway to the potential commercial launch of IMVT-1402 in Graves' disease under its current plan. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) No product revenue; Immunovant has never generated product revenue. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm) ## Risks on the record - Batoclimab failed two phase 3 thyroid eye disease trials and IMVT-1402 missed in cutaneous lupus, leaving one molecule carrying the company. [Source](https://www.immunovant.com/investors/news-events/press-releases/detail/86/immunovant-announces-topline-results-from-proof-of-concept) - Immunovant is in talks with licensor HanAll over batoclimab's future and warns a disagreement could lead to arbitration or litigation. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm) - Roivant controls a majority of the voting power, making Immunovant a controlled company exempt from some Nasdaq governance rules. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Immunovant? 3 out of 10, our negative view. Cash reaches the 2027 readouts, but the company is down to IMVT-1402 after a phase 3 miss and a lupus miss, in markets with approved FcRn drugs. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What is IMVT-1402? IMVT-1402, also called imeroprubart, is Immunovant's fully human antibody that blocks the FcRn receptor to lower IgG antibody levels. It is given as a subcutaneous injection and is in trials in Graves' disease, myasthenia gravis, rheumatoid arthritis, CIDP and Sjogren's disease. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm) ### Why did Immunovant stop batoclimab? Two phase 3 trials of batoclimab in thyroid eye disease did not meet their primary endpoint in April 2026. Immunovant then discontinued batoclimab in all indications to focus on IMVT-1402. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/exhibit9912026520.htm) ### What happened in Immunovant's cutaneous lupus trial? The 57-patient proof-of-concept study of IMVT-1402 did not reach statistical significance on CLASI-A percent change at week 12. Immunovant said it will stop development in cutaneous lupus. [Source](https://www.immunovant.com/investors/news-events/press-releases/detail/86/immunovant-announces-topline-results-from-proof-of-concept) ### How much cash does Immunovant have? Immunovant had $797.8 million in cash and cash equivalents at June 30, 2026. It says that provides runway to a potential commercial launch of IMVT-1402 in Graves' disease under its current plan. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) ### When will Immunovant report Graves' disease data? Immunovant expects topline data from its potentially registrational trials of IMVT-1402 in Graves' disease and myasthenia gravis in calendar year 2027. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) ### What is Immunovant's market cap? We do not publish live share prices. In its annual report, Immunovant, Inc. put the market value of shares held by non-affiliates (public float) at $1.25 billion as of Sep 30, 2025. Source ### Is Immunovant a smaller reporting company? SEC records list Immunovant, Inc.'s filer category as: Large accelerated filer. Source ### Where is Immunovant headquartered? SEC records list its business address as 1000 PARK FORTY PLAZA, DURHAM, NC, 27713. Source ### When does Immunovant's fiscal year end? Immunovant, Inc.'s fiscal year ends on March 31, per SEC records. Source ### What did Immunovant last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-09-03. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000106/imvt-20260902.htm) ### What was Immunovant called before? SEC records list these former names: Health Sciences Acquisitions Corp. Source ### What industry is Immunovant in? Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source ## Legal and investor matters Checked against Immunovant filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Note 10 of the 10-Q for the quarter ended 2026-06-30 (filed 2026-08-06) states that as of 2026-06-30 the company was not party to any material legal proceedings. The 10-K for the year ended 2026-03-31 (filed 2026-05-20) says a securities class action complaint filed in February 2021 alleged Exchange Act violations; the court entered judgment for the defendants in April 2024, and the 10-K says the litigation is concluded. [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm) 1. 2025-12-12 Financing Immunovant closes $550 million underwritten offering at $21.00 per share Immunovant sold 26.2 million shares of common stock in an underwritten offering at $21.00 per share under an underwriting agreement dated 2025-12-10 with Leerink Partners. Roivant Sciences, the company's controlling stockholder, participated. The offering closed on 2025-12-12 with gross proceeds of approximately $550 million before discounts, commissions and expenses. [Immunovant 8-K filed 2025-12-12](https://www.sec.gov/Archives/edgar/data/1764013/000119312525317577/d68980d8k.htm) 2. 2025-11-21 Governance Immunovant chief medical officer leaves in R&D leadership restructuring Michael Geffner ceased serving as chief medical officer effective 2025-11-21, in connection with the company's restructuring of its R&D leadership structure under CEO Eric Venker. Immunovant entered a separation agreement providing severance under his existing employment agreement and a standard release of claims in favor of the company. He will also provide certain consulting services during the transition. [Immunovant 8-K filed 2025-11-21](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/imvt-20251121.htm) 3. 2025-04-20 Governance Immunovant CEO Peter Salzmann and CFO Renee Barnett depart Peter Salzmann retired as chief executive officer effective 2025-04-20 and left the board effective 2025-04-18. Renee Barnett ceased serving as chief financial officer on 2025-04-20. The company entered a separation agreement with Salzmann providing severance under his existing employment agreement. The board appointed Eric Venker CEO effective 2025-04-21. [Immunovant 8-K filed 2025-04-21](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000078/imvt-20250418.htm) 4. 2025-01-13 Financing Immunovant agrees to $450 million private placement including Roivant On 2025-01-13 Immunovant entered a share purchase agreement under which institutional accredited investors, including Roivant Sciences, would buy 22,500,000 shares of common stock at $20.00 per share. Expected gross proceeds were approximately $450 million, with closing expected on or about 2025-01-15. The company said it would use net proceeds for pipeline development, working capital and general corporate purposes. [Immunovant 8-K filed 2025-01-13](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000007/imvt-20250113.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | IMVT-1402 (imeroprubart) | Graves' disease | Potentially registrational trial; topline data expected calendar 2027 [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) | | IMVT-1402 | Myasthenia gravis | Potentially registrational trial; topline data expected calendar 2027 [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) | | IMVT-1402 | Difficult-to-treat rheumatoid arthritis | Potentially registrational trial; open-label week-16 data reported; update expected second half of 2026 [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) | | IMVT-1402 | CIDP and Sjogren's disease | Potentially registrational trials; topline data expected calendar 2028 [Source](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/exhibit991202686.htm) | | IMVT-1402 | Cutaneous lupus erythematosus | Proof-of-concept trial missed primary endpoint; development stopped (Sept. 2026) [Source](https://www.immunovant.com/investors/news-events/press-releases/detail/86/immunovant-announces-topline-results-from-proof-of-concept) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IMVT on TradingView](https://www.tradingview.com/symbols/NASDAQ-IMVT/). ## SEC filings and registration - **SEC name**: Immunovant, Inc. - **CIK**: 1764013 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IMVT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: March 31 - **Filer category**: Large accelerated filer - **Business address**: 1000 PARK FORTY PLAZA, DURHAM, NC, 27713 - **Phone**: 917-410-3120 - **Shares outstanding**: 206,552,682 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Health Sciences Acquisitions Corp ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000106/imvt-20260902.htm) filed 2026-09-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000101/imvt-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm) filed 2026-08-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000092/imvt-20260721.htm) filed 2026-07-22 - [10-K](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000064/imvt-20260331.htm) filed 2026-05-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000062/imvt-20260520.htm) filed 2026-05-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000011/imvt-20251231.htm) filed 2026-02-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1764013/000176401326000010/imvt-20260206.htm) filed 2026-02-06 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001764013), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/immunovant/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Immunovant (IMVT) stock news, pipeline, cash and catalysts", 2026-10-31, https://aibio.space/companies/immunovant/